Northwest Biotherapeutics (NW Bio), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, said it is pursuing an intensive program of manufacturing preparations and planning as the company approaches top line data from its Phase III trial of DCVax-L. A cornerstone of this expanding program is completion of the Phase I buildout of the Sawston, UK manufacturing facility.   With construction crews working double shifts to accelerate this completion, the com...